Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

T cell costimulatory signalling in disease progression of angioimmunoblastic T cell lymphoma

EF 2014-15

Résumé
This research project is aimed at improving our understanding behind the disease progression of angioimmunoblastic T cell lymphoma (AITL), in order to help develop targeted cancer therapies. Developing specific cancer therapies for AITL is important as patients do no respond well to general chemotherapy treatments. Unfortunately, creating such targeted cancer therapies is extremely challenging, as the cellular mechanisms causing tumor growth is still unclear. AITL is a rare, but fast progressing type of blood cancer that is more prevalent in those over 60 years of age. The type of blood cell that becomes cancerous in AITL is a kind of white blood cell, the T lymphocyte (or T cell). T cells are important because they act as soldiers in the immune system to help fight off infections caused by foreign invaders. In AITL patients, what leads to mortality is not the tumor growth itself but rather these T cells which are abnormally increased in number. This causes an overactive immune response that turns on itself which can then start to attack the body's own cells and proteins. There are certain molecules on T cells that provide instructions for it to continue developing that may have become overactive in AITL tumor cells. By using mice models that will spontaneously develop tumors similar to human AITL patients where we can also control the delivery of these growth and survival instructions in T cells we hope to be able to uncover the mechanisms that initiate AITL cancer progression. In addition, we hope to harness this novel knowledge to develop therapies that can target these pathways in more effectively treat AITL patients.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
332503
Name
Witalis Mariko
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
T cell costimulatory signalling in disease progression of angioimmunoblastic T cell lymphoma
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angioimmunoblastic T Cell Lymphoma; Follicular; Lymphoma; Peripheral T Cell Lymphoma
Abstract
This research project is aimed at improving our understanding behind the disease progression of angioimmunoblastic T cell lymphoma (AITL), in order to help develop targeted cancer therapies. Developing specific cancer therapies for AITL is important as patients do no respond well to general chemotherapy treatments. Unfortunately, creating such targeted cancer therapies is extremely challenging, as the cellular mechanisms causing tumor growth is still unclear. AITL is a rare, but fast progressing type of blood cancer that is more prevalent in those over 60 years of age. The type of blood cell that becomes cancerous in AITL is a kind of white blood cell, the T lymphocyte (or T cell). T cells are important because they act as soldiers in the immune system to help fight off infections caused by foreign invaders. In AITL patients, what leads to mortality is not the tumor growth itself but rather these T cells which are abnormally increased in number. This causes an overactive immune response that turns on itself which can then start to attack the body's own cells and proteins. There are certain molecules on T cells that provide instructions for it to continue developing that may have become overactive in AITL tumor cells. By using mice models that will spontaneously develop tumors similar to human AITL patients where we can also control the delivery of these growth and survival instructions in T cells we hope to be able to uncover the mechanisms that initiate AITL cancer progression. In addition, we hope to harness this novel knowledge to develop therapies that can target these pathways in more effectively treat AITL patients.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Witalis, Mariko
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~